Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Nuclear Cardiology
Published in: Journal of Nuclear Cardiology 1/2009

01-02-2009 | ASNC Announcement

ASNC Announcement

Author: American Society of Nuclear Cardiology

Published in: Journal of Nuclear Cardiology | Issue 1/2009

Login to get access

Excerpt

ASNC is pleased to announce the publication of “Introduction of New Technology for Clinical Use.” This guideline is intended to provide an appropriate means of assessing new equipment function in conjunction with nuclear cardiology imaging. In order to provide information on the use of new technology, ASNC recommends minimum acceptable values for imaging acquisition and processing. This document is now available on the Web site of the Journal of Nuclear Cardiology at www.​onlinejnc.​com. …
Appendix
Available only for authorised users
Metadata
Title
ASNC Announcement
Author
American Society of Nuclear Cardiology
Publication date
01-02-2009
Publisher
Springer-Verlag
Published in
Journal of Nuclear Cardiology / Issue 1/2009
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-008-9030-4

Other articles of this Issue 1/2009

Journal of Nuclear Cardiology 1/2009 Go to the issue

Nuclear Cardiology Bullet

Endothelial dysfunction: the reversible coronary disease

ASNC Announcement

ASNC Announcement

ASNC Announcement

ASNC Announcement

ASNC Announcement

ASNC Announcement

Original Article

The RegEx trial: a randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A2A adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging

Original Article

Impaired myocardial oxidative metabolism in the remote normal region in patients in the chronic phase of myocardial infarction and left ventricular remodeling

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits